
BL-1249
CAS No. 18200-13-0
BL-1249 ( —— )
产品货号. M33294 CAS No. 18200-13-0
BL-1249 是一种非甾体抗炎剂 (NSAID) 和钾通道激活剂,可有效激活 K2P2.1 (TREK-1) 和 K2P10.1 (TREK-2),EC50 值分别为 5.5 μM 和 8.0 μM。BL-1249 在细胞外激活了所有 TREK 亚家族成员,但对其他 K2P 亚家族没有影响。BL-1249 对膀胱的选择性 (EC50 为 1.26 μM) 比对血管组织 (EC50 为 21.0 μM) 更高。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥620 | 有现货 |
![]() ![]() |
5MG | ¥912 | 有现货 |
![]() ![]() |
10MG | ¥1445 | 有现货 |
![]() ![]() |
25MG | ¥2127 | 有现货 |
![]() ![]() |
50MG | ¥2909 | 有现货 |
![]() ![]() |
100MG | ¥4995 | 有现货 |
![]() ![]() |
500MG | ¥10328 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称BL-1249
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述BL-1249 是一种非甾体抗炎剂 (NSAID) 和钾通道激活剂,可有效激活 K2P2.1 (TREK-1) 和 K2P10.1 (TREK-2),EC50 值分别为 5.5 μM 和 8.0 μM。BL-1249 在细胞外激活了所有 TREK 亚家族成员,但对其他 K2P 亚家族没有影响。BL-1249 对膀胱的选择性 (EC50 为 1.26 μM) 比对血管组织 (EC50 为 21.0 μM) 更高。
-
产品描述BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM).
-
体外实验BL-1249 produces a concentration-dependent membrane hyperpolarization of cultured human bladder myocytes, assessed as either a reduction in fluorescence of the voltage-sensitive dye bis-(1,2-dibutylbarbituric acid)trimethine oxonol (EC50 of 1.26 μM) or by direct electrophysiological measurement EC50 of 1.49 μM). BL-1249 produced a concentration-dependent hyperpolarization with an EC50 of 21.0 μM in human aortic smooth muscle cells.In in vitro organ bath experiments, BL-1249 produces a concentration-dependent relaxation of 30 mM KCl-induced contractions in rat bladder strips (EC50 of 1.12 μM), yet has no effect on aortic strips up to the highest concentration tested (10 μM). The bladder relaxation produced by BL-1249 is partially blocked by Ba2+ (1 and 10 mM).BL-1249 is a selective agonist of the TREK subfamily when applied extracellularly, having preferential action on K2P2.1(TREK-1) and K2P10.1(TREK-2) over K2P4.1(TRAAK) and establish that its mechanism of action relies on gating at the selectivity filter C-type gate.
-
体内实验BL-1249 (1 mg/kg) inhibits isovolumic bladder contractions in vivo. The short duration of the effect of BL-1249 on bladder contraction ( 30 min) is likely due to a fast elimination half-life of the compound after i.v. administration (0.69 h). BL-1249 (1 mg/kg) has little effect on mean arterial blood pressure, an observation again consistent with the in vitro bladder to vascular relaxant selectivity.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点Potassium Channel
-
受体Potassium Channel
-
研究领域——
-
适应症——
化学信息
-
CAS Number18200-13-0
-
分子量291.35
-
分子式C17H17N5
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 50 mg/mL (171.61 mM; 超声助溶 (<60°C)
-
SMILESC1CCc2c(C1)cccc2Nc1ccccc1-c1nnn[nH]1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Tertyshnikova S, et al. BL-1249 [(5,6,7,8-tetrahydro-naphthalen-1-yl)-[2-(1H-tetrazol-5-yl)-phenyl]-amine]: a putative potassium channel opener with bladder-relaxant properties. J Pharmacol Exp Ther. 2005 Apr;313(1):250-9.?
产品手册




关联产品
-
Retigabine dihydroch...
瑞替加滨二盐酸盐是一种抗惊厥药,用作有治疗经验的成年患者部分性癫痫的辅助治疗。作用机制涉及打开神经元 K(V)7.2-7.5(以前称为 KCNQ2-5)电压激活的 K(+) 通道。在分化的 PC12 细胞中,瑞替加滨增强了利诺吡啶敏感电流。
-
KCNQ1 activator-1?
2-Piperidinecarboxamide, N-[4-(4-甲氧基苯基)-2-thiazolyl]-1-(苯基磺酰基)- 是一种有效的 KCNQ1 通道激活剂,可用于长 QT 综合征 (LQTS) 研究。
-
BMS-813160
BMS-813160是第一个进入心血管临床开发的双重CCR2/CCR5拮抗剂。